Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099   26/07/2024
146,80 USD (+0,48%)
(+0,48%)   26/07/2024
Grafiek Neurocrine Biosciences, Inc. Grafiek Neurocrine Biosciences, Inc.
donderdag 1 augustus 2024, 13:00
Kwartaalcijfers (2de kwartaal)

Neurocrine Biosciences, Inc. in het nieuws

18 juli 2024 · Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing · Persbericht

11 juli 2024 · Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results · Persbericht

1 juli 2024 · Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH · Persbericht

3 juni 2024 · Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024 · Persbericht

3 juni 2024 · Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine · Persbericht

3 juni 2024 · Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine · Persbericht

29 mei 2024 · Neurocrine Biosciences to Participate at Investor Conferences in June · Persbericht

28 mei 2024 · Neurocrine Biosciences Announces CEO Succession Plan · Persbericht

28 mei 2024 · Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024 · Persbericht

21 mei 2024 · Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules · Persbericht

Profiel Neurocrine Biosciences, Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.neurocrine.com

Hoofdzetel: San Diego, California vlag Verenigde Staten

CEO: Kevin Gorman

Werknemers: 1.252

Aandelen Neurocrine Biosciences, Inc.

Beurswaarde: 14,70 miljard USD

Effecten: 100,64 miljoen

Winst per aandeel (12 maand):  PLUS

Koers-winstverhouding:  PLUS

Beta: 0,32

Mijn selecties